ATI RN
MSN 570 Advanced Pathophysiology Final 2024
1. What is a cause of the crystallization within the synovial fluid of the joint affected by gouty arthritis?
- A. Destruction of proteoglycans
- B. Underexcretion of uric acid
- C. Overexcretion of uric acid
- D. Increased absorption of uric acid
Correct answer: B
Rationale: The correct answer is B: Underexcretion of uric acid. In gouty arthritis, the crystallization within the synovial fluid of the affected joint is caused by the underexcretion of uric acid, leading to the accumulation and subsequent crystallization of urate crystals. Choice A, destruction of proteoglycans, is incorrect as it is not directly related to the crystallization process in gouty arthritis. Choice C, overexcretion of uric acid, is incorrect because gout is primarily associated with underexcretion or decreased excretion of uric acid rather than overexcretion. Choice D, increased absorption of uric acid, is also incorrect as the primary issue in gouty arthritis is the body's inability to properly eliminate uric acid.
2. A patient with benign prostatic hyperplasia (BPH) is prescribed finasteride (Proscar). What outcome should the nurse expect to observe if the medication is effective?
- A. Increased urinary frequency and urgency
- B. Decreased prostate size
- C. Increased prostate size
- D. Decreased blood pressure
Correct answer: B
Rationale: The correct answer is B: Decreased prostate size. Finasteride is a medication used to reduce the size of the prostate gland in patients with BPH. By decreasing the size of the prostate, symptoms such as urinary frequency and urgency are improved. Choice A is incorrect as the medication aims to decrease, not increase, urinary symptoms. Choice C is incorrect because the goal of finasteride is to reduce, not increase, the prostate size. Choice D is also incorrect as finasteride is not indicated for lowering blood pressure.
3. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary therapeutic action of this medication?
- A. It stimulates the formation of new bone.
- B. It decreases bone resorption and increases bone density.
- C. It increases calcium absorption in the intestines.
- D. It increases the excretion of calcium through the kidneys.
Correct answer: B
Rationale: The correct answer is B. Raloxifene works by decreasing bone resorption and increasing bone density, which helps in the prevention and treatment of osteoporosis. Choice A is incorrect as raloxifene does not directly stimulate the formation of new bone. Choice C is incorrect because raloxifene does not primarily affect calcium absorption in the intestines. Choice D is incorrect as raloxifene does not increase the excretion of calcium through the kidneys.
4. A nurse is teaching a patient about the use of testosterone gel for the treatment of hypogonadism. What important instruction should the nurse provide?
- A. Apply the gel after showering, and allow it to dry completely before dressing.
- B. Apply the gel to the genitals for maximum absorption.
- C. Apply the gel before bedtime to enhance absorption during sleep.
- D. Apply the gel to the face and neck for improved results.
Correct answer: A
Rationale: The correct instruction is to apply testosterone gel after showering and allow it to dry completely before dressing. This helps prevent the transfer of the gel to others and ensures proper absorption. Choice B is incorrect because the gel should not be applied to the genitals. Choice C is incorrect as there is no specific benefit to applying the gel before bedtime. Choice D is incorrect as the gel should not be applied to the face and neck for the treatment of hypogonadism.
5. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary mechanism of action for this medication?
- A. Raloxifene decreases bone resorption, which helps to maintain or increase bone density.
- B. Raloxifene increases calcium absorption in the intestines, which helps build stronger bones.
- C. Raloxifene stimulates new bone formation by increasing osteoblast activity.
- D. Raloxifene decreases calcium excretion by the kidneys, helping to maintain bone density.
Correct answer: A
Rationale: Raloxifene decreases bone resorption, which helps to maintain or increase bone density, making it effective in the prevention and treatment of osteoporosis.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access